ACTRN12618000131257已完成1 期
Phase I, First in Human (FIH), Randomised, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study in Healthy Volunteers with Mild to Moderate Onychomycosis.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Hexima Ltd
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Confirmation of onychomycosis by mycological staining and/or culture from affected great toenail(s).
- •2. Appearance of onychomycosis involving at least 20% but not more than 70% of one (or both) affected Great toenail(s) as determined by visual inspection after the nail has been trimmed.
- •2. The combined thickness of the distal nail plate at the associated hyperkeratotic nail bed is < 3 mm.
- •3. Adult male and females, 18 to 65 years of age (inclusive) at the time of screening.
- •4. Medically healthy with clinically insignificant screening results (e.g. laboratory profiles, medical history, ECGs, physical exam), as judged by the PI.
- •5. Negative urine drug screen/alcohol breath test at screening and Day 1.
- •6. Voluntary consent to participate in the study.
- •7. Body Mass Index (BMI) between 17.5 and 35 inclusive.
- •8. Participants must be instructed to use a highly effective, double barrier contraception (both male and female partners) during the study and for 1 month (females) and 3 months (males) following the final dose of HXP124.
- •Double barrier contraception is defined as a condom AND one other form of the following:
- •a. Birth control pills (The Pill)
- •b. Depot or injectable birth control
- •c. IUD (Intrauterine Device)
- •d. Birth Control Patch (e.g., Ortho Evra)
- •e. NuvaRing®
- •f. Surgical sterilisation at least 6 months prior to screening visit. i.e., tubal ligation or hysterectomy for women or vasectomy for men.
- •9. Males must not donate sperm for at least 3 months post-dose of the last study treatment. Male partners of female participants and female partners of male participants must also use contraception, if they are of childbearing potential. Females of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1. Females not of childbearing potential must be post-menopausal (defined as cessation of regular menstrual periods for at least 12 months), confirmed by follicle stimulating hormone (FSH) level > 40 mIU/mL.
- •Rhythm methods will not be considered as highly effective methods of birth control. Participant abstinence for the duration of the study and for 1 month (females) and 3 months (males) after the last dose of HXP124 is acceptable.
排除标准
- •1. History of allergy to any of the excipients in HXP124.
- •2. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
- •3. Have any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the study.
- •4. Females who are pregnant or lactating.
- •5. Unwilling to refrain from the use of nail cosmetics such as clear and/or coloured nail lacquers from the screening visit until the end of the study.
- •6. Administration of investigational product (IP) in another trial within 30 days prior to the first study drug administration.
- •7. Failure to satisfy the principal investigator (PI) of fitness to participate for any other reason.
- •8. Clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardise his/her safety.
- •9. Diabetes mellitus requiring treatment other than diet and exercise.
- •10. Has not undergone the specified washout period(s) for the following topical preparations or if the participant requires the concurrent use of any of the following topical medications:
- •a. Topical antifungal applied to the feet (does not include antifungals for treatment of Tinea pedis during the study: 4 weeks)
- •b. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks
- •11. Has not undergone the specified washout period(s) for the following systemic medications or the subject requires the concurrent use of any of the following systemic medications:
- •a. Corticosteroids (including intramuscular injections): 2 weeks
- •b. Antifungals for treatment of onychomycosis or any systemic antifungal
- •with known activity against dermatophyte: 12 weeks
- •12. Use of systemic immunomodulators in the past 4 weeks.
- •13. Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary disorders, onychogryphosis, trauma to the nail(s) to be treated.
研究者
相似试验
已完成
1 期
A first in human study to evaluate the safety and immune response to a vaccine for the treatment of a respiratory virus, when administered into the arm in healthy adult participants.Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesRespiratory Syncytial Virus InfectionACTRN12618000948291Advanced Vaccine Laboratories Pty Ltd60
招募中
1 期
Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection.Hepatitis B, ChronicCTIS2023-510020-68-00GlaxoSmithKline Biologicals115
进行中（未招募）
1 期
A study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) viral vector vaccines and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infectioChronic hepatitis BMedDRA version: 20.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001452-55-DEGlaxoSmithKline Biologicals158
进行中（未招募）
1 期
A study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GlaxoSmithKline (GSK) Biologicals' HBV (Hepatitis B Virus) viral vector vaccines and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infectioEUCTR2017-001452-55-BEGlaxoSmithKline Biologicals158
已完成
1 期
A first-in-human, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose (SAD/MAD) study of ENN0403 in healthy subjectsDiabetic retinopathyonalcoholic steatohepatitis (NASH)Nonalcoholic steatohepatitis (NASH)Inflammatory and Immune System - Other inflammatory or immune system disordersPulmonary fibrosisACTRN12622001067763EnnovaBio Australia Pharmaceuticals Pty Ltd69